CRISPR Therapeutics AG (NASDAQ: CRSP) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $53.00 price target on the stock.
LowReport
CRISPR Therapeutics AG (NASDAQ: CRSP) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $53.00 price target on the stock.
CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Barclays PLC from $59.00 to $55.00. They now have an "equal weight" rating on the stock.
LowReport
CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Barclays PLC from $59.00 to $55.00. They now have an "equal weight" rating on the stock.
CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $84.00 price target on the stock.
LowReport
CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $84.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: